← Back

Wire · opportunities

Revolution Medicines drug Rasonoque shows promise against lung cancer

Published

5 September 2026

Topic

opportunities

Sectors

Biotech

Geography

United States

Source

Read at fox.com

Verified

Fusion42 · 5 September 2026 · Fusion42 review

Revolution Medicines' drug Rasonoque, already FDA-approved for metastatic pancreatic cancer, shows promising new clinical trial results for treating advanced lung cancer.

This Wire brief sits within Fusion42's coverage of Biotech, and 51 sources have reported it between 26 Aug 2026 and 5 Sep 2026.

◆ The Wire takeaway

You can approach oncology portfolios that focus on lung cancer with a new drug approval pathway opening soon. Investors and partners may shift quickly towards therapies building on Rasonoque's advance.

Coverage

51 sources · first reported 26 Aug 2026 · latest 5 Sep 2026

Topics

Biotechclinical-trialslung-cancerFDA-approvalcancer-treatment